RecruitingPhase 2NCT07499362
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Principal Investigator
- Medical ResponsibleMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Intervention
- Pimicotinib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Research Site, Darmstadt, Germany
Collaborators
Merck KGaA, Darmstadt, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07499362 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05417789Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)SynOx Therapeutics Limited
- ACTIVE NOT RECRUITINGPHASE3NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Abbisko Therapeutics Co, Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell TumorDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo
- ACTIVE NOT RECRUITINGPHASE3NCT04488822A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.